search
Back to results

Rate of Bronchopulmonary Dysplasia in Preterms Neonates: a Trial Comparing SMOFlipid and Medialipide (SMOF)

Primary Purpose

Preterm Neonates

Status
Withdrawn
Phase
Phase 4
Locations
France
Study Type
Interventional
Intervention
SMOFlipid®
Medialipide®
Sponsored by
Hospices Civils de Lyon
About
Eligibility
Locations
Arms
Outcomes
Full info

About this trial

This is an interventional treatment trial for Preterm Neonates focused on measuring Preterm neonates

Eligibility Criteria

6 Hours - 1 Day (Child)All SexesDoes not accept healthy volunteers

Inclusion Criteria:

  • Preterm neonates with gestational age < 29 weeks and / or birth weight < 1000 g
  • Admission in the Intensive Care Unit within 6 h after birth
  • IV Lipid Emulsion (LE) started latest at first day of life
  • Anticipated duration of Parenteral Nutrition >10 days
  • Informed consent from legal representative

Exclusion Criteria:

  • Inherited metabolic diseases
  • Major congenital malformations
  • Participation to another study evaluating any kind of medications

Sites / Locations

  • Hopital Femme Mère Enfant

Arms of the Study

Arm 1

Arm 2

Arm Type

Experimental

Active Comparator

Arm Label

SMOF

Medialipide®

Arm Description

parenteral nutrition using SMOFlipid® (FreseniusKabi France, Sèvres, France)

parenteral nutrition using Medialipide® 20% (B Braun Medical, Boulogne, France)

Outcomes

Primary Outcome Measures

Rate of other free radical diseases
Free radical diseases include: intraventricular hemorrhage (IVH) > grade II, retinopathy of prematurity (ROP) > grade II, and necrotizing enterocolitis (NEC) > grade IA (Bell classification).

Secondary Outcome Measures

Weight gain
Weight gain in g/kg/j according to the following formulae: 1000 * ((weight on day 28 or week 36 - birth weight)/((weight on day 28 or week 36 + birth weight)/2)) / number of days
Weight gain
Weight gain in g/kg/j according to the following formulae: 1000 * ((weight on day 28 or week 36 - birth weight)/((weight on day 28 or week 36 + birth weight)/2)) / number of days
Growth velocity
Length growth velocity in cm/week at day 28 according to the following formulae: (length on day 28 - length at birth) / number of weeks
Growth velocity
Length growth velocity in cm/week at week 36 corrected age according to the following formulae: (length on week 36 - length at birth) / number of weeks
Head circumference growth velocity
Head circumference growth velocity in cm/week according to the following formulae: (head circumference on day 28 - head circumference at birth) / number of weeks
Head circumference growth velocity
Head circumference growth velocity in cm/week according to the following formulae: (head circumference on week 36 - head circumference at birth) / number of weeks

Full Information

First Posted
July 29, 2016
Last Updated
July 22, 2019
Sponsor
Hospices Civils de Lyon
search

1. Study Identification

Unique Protocol Identification Number
NCT02853253
Brief Title
Rate of Bronchopulmonary Dysplasia in Preterms Neonates: a Trial Comparing SMOFlipid and Medialipide
Acronym
SMOF
Official Title
Rate of Bronchopulmonary Dysplasia in Preterms Neonates Less Than 29 Weeks' Gestational Age and / or With Birth Weight Less Than 1000 g: a Double Blind Randomized Controlled Multicenter Trial Comparing SMOFlipid and Medialipide
Study Type
Interventional

2. Study Status

Record Verification Date
July 2019
Overall Recruitment Status
Withdrawn
Why Stopped
scientific question reconsidered
Study Start Date
January 2017 (undefined)
Primary Completion Date
May 2019 (Anticipated)
Study Completion Date
May 2019 (Anticipated)

3. Sponsor/Collaborators

Responsible Party, by Official Title
Sponsor
Name of the Sponsor
Hospices Civils de Lyon

4. Oversight

Data Monitoring Committee
Yes

5. Study Description

Brief Summary
SMOF is a large double blind placebo-controlled randomized clinical trial aiming to compare the rate of bronchopulmonary dysplasia (BPD) at 36 weeks corrected age in premature infants < 29 weeks and / or with birth weight < 1000 g receiving either SMOFlipid® or Medialipide® 20%. This study will offer new information for optimizing the management of preterms requiring parenteral nutrition. The investigators hypothesis is that the composition of SMOFlipid may decrease lipid peroxidation and oxidative stress in preterms, resulting in a lower incidence of BPD.

6. Conditions and Keywords

Primary Disease or Condition Being Studied in the Trial, or the Focus of the Study
Preterm Neonates
Keywords
Preterm neonates

7. Study Design

Primary Purpose
Treatment
Study Phase
Phase 4
Interventional Study Model
Parallel Assignment
Masking
ParticipantCare ProviderInvestigatorOutcomes Assessor
Allocation
Randomized
Enrollment
0 (Actual)

8. Arms, Groups, and Interventions

Arm Title
SMOF
Arm Type
Experimental
Arm Description
parenteral nutrition using SMOFlipid® (FreseniusKabi France, Sèvres, France)
Arm Title
Medialipide®
Arm Type
Active Comparator
Arm Description
parenteral nutrition using Medialipide® 20% (B Braun Medical, Boulogne, France)
Intervention Type
Dietary Supplement
Intervention Name(s)
SMOFlipid®
Intervention Description
SMOFlipid® (FreseniusKabi France, Sèvres, France). It is a 3rd generation LE containing a physical mixture of soybean oil (30%), MCT (30%), olive oil (25%) and fish oil (15%). Its ratio omega6/omega 3 is 2,5/1. SMOF will be initiated within the 1st day of life of neonates and will be prescribed daily by the attending physician following these guidelines: initiation rate: 1 g/kg/day; daily increase: 0.5 to 1 g/kg/day ; target: 3 to 4 g/kg/day. All included preterms will receive nutritional support according to a single protocol based on the ESPGHAN recommendations: parenteral glucose and amino acids (Primene 10%, Clintec Parenteral, Maurepas, France) soon after birth (in their 1st day of life). Initiation rate of parenteral glucose and amino acids will be 6 to 8 g/kg/day and 2 g/kg/day respectively. The daily increase of parenteral glucose and amino acids will be 1 to 2 g/kg/day and 0.5 g/kg/day respectively, for a target rate of 14 to 17 g/kg/day and 3.5 g/kg/day respectively.
Intervention Type
Dietary Supplement
Intervention Name(s)
Medialipide®
Intervention Description
Medialipide® 20% (B Braun Medical, Boulogne, France). It is a second generation LE containing soybean oil (50%) and MCT (50%). Its ratio omega6/omega 3 is 7/4. Medialipide will be initiated within the 1st day of life of neonates and will be prescribed daily by the attending physician following these guidelines: initiation rate: 1 g/kg/day ; daily increase: 0.5 to 1 g/kg/day; target: 3 to 4 g/kg/day. All included preterms will receive nutritional support according to a single protocol based on the ESPGHAN recommendations: parenteral glucose and amino acids (Primene 10%, Clintec Parenteral, Maurepas, France) soon after birth (in their 1st day of life). Initiation rate of parenteral glucose and amino acids will be 6 to 8 g/kg/day and 2 g/kg/day respectively. The daily increase of parenteral glucose and amino acids will be 1 to 2 g/kg/day and 0.5 g/kg/day respectively, for a target rate of 14 to 17 g/kg/day and 3.5 g/kg/day respectively.
Primary Outcome Measure Information:
Title
Rate of other free radical diseases
Description
Free radical diseases include: intraventricular hemorrhage (IVH) > grade II, retinopathy of prematurity (ROP) > grade II, and necrotizing enterocolitis (NEC) > grade IA (Bell classification).
Time Frame
36 weeks corrected age
Secondary Outcome Measure Information:
Title
Weight gain
Description
Weight gain in g/kg/j according to the following formulae: 1000 * ((weight on day 28 or week 36 - birth weight)/((weight on day 28 or week 36 + birth weight)/2)) / number of days
Time Frame
at day 28
Title
Weight gain
Description
Weight gain in g/kg/j according to the following formulae: 1000 * ((weight on day 28 or week 36 - birth weight)/((weight on day 28 or week 36 + birth weight)/2)) / number of days
Time Frame
week 36 corrected age
Title
Growth velocity
Description
Length growth velocity in cm/week at day 28 according to the following formulae: (length on day 28 - length at birth) / number of weeks
Time Frame
at day 28
Title
Growth velocity
Description
Length growth velocity in cm/week at week 36 corrected age according to the following formulae: (length on week 36 - length at birth) / number of weeks
Time Frame
week 36 corrected age
Title
Head circumference growth velocity
Description
Head circumference growth velocity in cm/week according to the following formulae: (head circumference on day 28 - head circumference at birth) / number of weeks
Time Frame
at day 28
Title
Head circumference growth velocity
Description
Head circumference growth velocity in cm/week according to the following formulae: (head circumference on week 36 - head circumference at birth) / number of weeks
Time Frame
at week 36 corrected age

10. Eligibility

Sex
All
Minimum Age & Unit of Time
6 Hours
Maximum Age & Unit of Time
1 Day
Accepts Healthy Volunteers
No
Eligibility Criteria
Inclusion Criteria: Preterm neonates with gestational age < 29 weeks and / or birth weight < 1000 g Admission in the Intensive Care Unit within 6 h after birth IV Lipid Emulsion (LE) started latest at first day of life Anticipated duration of Parenteral Nutrition >10 days Informed consent from legal representative Exclusion Criteria: Inherited metabolic diseases Major congenital malformations Participation to another study evaluating any kind of medications
Overall Study Officials:
First Name & Middle Initial & Last Name & Degree
Olivier CLARIS, Pr
Organizational Affiliation
Hospices Civils de Lyon
Official's Role
Principal Investigator
Facility Information:
Facility Name
Hopital Femme Mère Enfant
City
Bron
Country
France

12. IPD Sharing Statement

Plan to Share IPD
No

Learn more about this trial

Rate of Bronchopulmonary Dysplasia in Preterms Neonates: a Trial Comparing SMOFlipid and Medialipide

We'll reach out to this number within 24 hrs